|
|
|
| Relationship Between HOMA-IR HOMA-ISLET and TSH in Patients with Type 2 Diabetes Mellitus and Subclinical Hypothyroidism |
| GAO Tingting, ZHOU Yurong, GE Yong, et al |
| Chuzhou First People's Hospital, Anhui Chuzhou 239000, China |
|
|
|
|
Abstract Objective: To investigate the relationship between the insulin resistance index (HOMA-IR), islet β-cell function index (HOMA-ISLET), and thyroid-stimulating hormone (TSH) in patients with type 2 diabetes mellitus (T2DM) complicated by subclinical hypothyroidism (SCH). Methods: One hundred and two patients with T2DM and SCH who received treatment at the hospital from October 2019 to October 2024 were selected and divided into two groups based on TSH levels: the normal group (n=49) and the elevated group (n=53). The normal group had TSH levels of 0.3-3.6 mIU/L, while the elevated group had TSH levels > 3.6 mIU/L. Basic data for both groups were collected, and blood glucose indices were measured for all patients to calculate HOMA-IR and HOMA-ISLET. Basic data, HOMA-IR, and HOMA-ISLET were compared between the two groups. The Spearman method was used to analyze the correlation between HOMA-IR, HOMA-ISLET, and TSH. ROC curve analysis was performed to assess the predictive value of HOMA-IR and HOMA-ISLET on TSH levels. Results: There were no significant differences in basic data between the two groups (P>0.05). Compared with the normal group, the HOMA-IR level was higher and the HOMA-ISLET level was higher in the elevated group (P<0.05). HOMA-IR and HOMA-ISLET were positively correlated with TSH levels (P<0.05). ROC curve analysis showed that HOMA-IR had high predictive specificity for TSH elevation, while HOMA-ISLET had a high area under the curve and sensitivity. Conclusion: HOMA-IR and HOMA-ISLET are positively correlated with TSH levels in patients with type 2 diabetes mellitus combined with subclinical hypothyroidism. HOMA-IR and HOMA-ISLET have certain predictive value for TSH elevation, with HOMA-ISLET demonstrating higher predictive efficacy.
|
|
|
|
|
|
[1] Atila C,Loughrey PB,Garrahy A,et al.Central diabetes insipidus from a patient's perspective:management,psychological co-morbidities,and renaming of the condition:results from an international web-based survey[J].Lancet Diabetes Endocrinol,2022,10(10):700-709.
[2] 吴小颖,陈彤华,邢雪凤,等.HbA1c、E_(2)、C肽对围绝经期、绝经后2型糖尿病患者合并亚临床甲状腺功能减退症的诊断价值[J].中国现代医学杂志,2023,33(1):24-31.
[3] Tahapary DL,Pratisthita LB,Fitri NA,et al.Challenges in the diagnosis of insulin resistance:focusing on the role of HOMA-IR and Tryglyceride/glucose index[J].Diabetes Metab Syndr,2022,16(8):102581.
[4] Zhu Q,Kang J,Xu G,et al.Traditional Chinese medicine Shenqi compound to improve lower extremity atherosclerosis of patients with type 2 diabetes by affecting blood glucose fluctuation:Study protocol for a randomized controlled multicenter trial[J].Medicine (Baltimore),2020,99(11):19501.
[5] 李妍.前列地尔对2型糖尿病合并脑梗死患者神经功能、炎症因子、血液流变学的影响[J].心脑血管病防治,2021,21(1):79-81.
[6] Zhang AMY,Wellberg EA,Kopp JL,et al.Hyperinsulinemia in obesity,inflammation,and cancer[J].Diabetes Metab,2021,45(3):285-311.
[7] 王斐.多囊卵巢综合征患者正常促甲状腺激素水平与糖脂代谢及胰岛素抵抗关系[J].中国计划生育学杂志,2021,29(4):767-770.
[8] 王文杏,李云,范运娟,等.妊娠期甲状腺功能减退患者胰岛素抵抗水平及与甲状腺激素水平、妊娠结局的相关性[J].临床和实验医学杂志,2023,22(22):2416-2420. |
|
|
|
2025, Vol. 31 
